Blood:III Trial: Thrombosis in myeloma patients treated with different protocols

Newly diagnosed patients treated with immunomodulation drugs (IMiDs) have a higher risk of venous thrombosis (VTE), but there is no data from a large number of forward-looking queuesThis study is a Phase III randomized controlled trial for NDMM that treats patients who met and did not meet the transplant conditions before and after the release of the thrombosis prevention guidelinesA total of 1936 cases of myeloma IX and 4358 cases of myeloma XI blood clot prognosis data were reportedpatients with myeloma IX had a higher risk of VTE (22.5% vs 16.1%; HR 1.46, 95% CI 11.1111.13) compared to those who were assigned to CVAD (cyclophosphamide, cinewe, doroubixandal and dexamethasone) in the patients with THE level of CTD (cyclophosphamide, ciderinn, dojoscoucidium and dexamethasone)For patients who did not qualify for the transplant, patients who were assigned to the CTDa (Enhanced CTD) induction group had a higher VTE risk (16.0% vs 4.1%; HR: 4.25, 95% CI: 2.50-7.20) compared to the MP (Mefalen and Strong Pine) groupin patients with myeloma XI, there was no significant difference between the risk of VTE or arterial embolism in patients who met the transplant criteria in the CRD (cyclophosphamide, reinamine and dexamethasone) and CTD groupsFor patients who did not qualify for transplantation, there was no significant difference in the risk of VTE after being assigned to CRDa (enhanced class CRD) and CTDa groupsHowever, the risk of arterial embolism was higher in patients in the CRDa group than in the CTDa group (3.1% vs 1.6%; aHR: 1.91, 95% CI: 1.02-3.57)thrombosis occurs almost all within 6 months of the start of treatmentIn addition to poor overall survival (OS) in patients with myeloma XI who had an arterial event, thrombosis was not associated with no progression or poor OSMyeloma XI trial program incorporates IMWG thrombosis prevention recommendations, compared with myeloma IX, under the same program, more patients are treated with thrombosis, the incidence of VTE is lowerhowever, despite IMWG-directed thrombosis prevention, thrombosis is still frequent, suggesting that new prevention methods are still needed